- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03649243
Propolis as Adjuvant in the Healing of Human Diabetic Foot Wounds
Propolis as Adjuvant in the Healing of Human Diabetic Foot Wounds Receiving Care in Diagnostic and Treatment Center From Regional Hospital of Talca
The general objective of the project is "To evaluate the effect of the administration of propolis extract as a coadjuvant in the treatment of diabetic foot ulcers in patients receiving cures in the Specialties Polyclinic of the Regional Hospital of Talca, Maule Region", which will be used Propolis produced in the area, (Laboratorios Rotterdam Ltda.) used in topical form.
It has been described that among the benefits produced by Propolis, is its anti-inflammatory, antioxidant effect and that the topical application of it is well tolerated, improving the healing of human diabetic foot ulcer.
Study Overview
Detailed Description
They will be invited to enter the study, at no cost, to 72 patients seen in the Specialty Clinic of the Regional Hospital of Talca, who have a history of diabetic feet with ulcers and who are in treatment with cures and who meet the following criteria. inclusion:
- People with Diabetes Mellitus (DM), older than 18 years, type 1 or 2, with known evolution of their diabetes between 2 and 15 years.
- Carriers of diabetic foot ulcers
- Without other important diseases
Patients who present the following criteria will be excluded from the study:
- Propolis allergy
- Serious circulation problems
- Foot burns
- Psychological conditions, or distances that prevent regular attendance to all required cures.
According to the programmed, 72 people will be admitted to the study, of which half will receive Propolis application on their wound at the end of their usual healing, for a maximum period of 75 days; while the other half will maintain the usual cure without Propolis.
All participants must maintain the usual treatment of their illness, as well as the usual type and frequency of their cures and maintain their physical activity according to the medical indication during this period. After 75 days, those who did not receive Propolis will have the possibility to receive it in the same way for 75 days.
All patients in the study must have a recent basic evaluation of their Diabetes performed in their office or the Specialties Polyclinic of the Regional Hospital of Talca at the beginning (up to 30 days prior) and at the end of the treatment, consisting of glycemia and glycosylated hemoglobin.
Tissue samples will be taken from your wound to make measurements of inflammation, degree of healing, infectionand oxidative stress, at the beginning, week 3, 6 and at the end of the study (75 days). The sample at the end of the study will only be obtained if the wound is still open.
In addition, at the beginning and at the end a blood sample of 5cc will be taken to measure levels of inflammatory markers and oxidative stress in blood.
These samples will be taken in the same Specialty Clinic of the Regional Hospital of Talca, but they will be transferred to be processed in the Clinical Biochemistry Laboratory of the Faculty of Health Sciences and the School of Medicine of the University of Talca. . Samples will be stored frozen at -80 ° C, under a code to guarantee confidentiality, for a period of 2 years, after which they will be eliminated.
During the last care / healing that the nurse does to the patient, you will be asked to complete a survey with questions to collect personal opinions about the effect of topical propolis.
Benefits: It has been described that the topical application of Propolis can improve the healing of human diabetic foot ulcer.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- DM type 1 or 2 with complicated foot diabetics wounds.
- 18-80 years old
Exclusion Criteria:
- Propolis allergy
- Critical ischemia
- Severe infection
- Psycho-social conditions that avoid regular attendance at health aid.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Propolis group
The patients receive propolis (3% in Propylene Glycol) in all the wound surface in each healing until cicatrisation or at least 8 weeks.
(n=20)
|
Propolis was added at the site of injury, 3 puff for any wound in the foot of patients.
All the patients decide voluntary if they want to receive the propolis spray treatment or only receive they normal wound healing care.
|
control group
the patients received the same care in the healing of their wounds, but no new component or propolis 3% was administered (n=8)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
allergenic to propolis analysis
Time Frame: through study completion, with an average of 8 months
|
All patients were analyzed for the probability of allergenic reaction.
It was done on the dermal reaction compared to the reaction to a single dose of histamine.
|
through study completion, with an average of 8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
obtaining biopses
Time Frame: the first biopses was obtained at time zero of enrollment and every 4 weeks, until the wound close or at time 12 weeks (end point of the biopses obtaining)
|
obtaining wound biopsies for histological and molecular analysis
|
the first biopses was obtained at time zero of enrollment and every 4 weeks, until the wound close or at time 12 weeks (end point of the biopses obtaining)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: elba Leiva, Mg, University of Talca
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Skin Diseases
- Endocrine System Diseases
- Diabetic Angiopathies
- Leg Ulcer
- Skin Ulcer
- Diabetes Complications
- Diabetes Mellitus
- Diabetic Neuropathies
- Foot Ulcer
- Diabetes Mellitus, Type 2
- Diabetic Foot
- Anti-Infective Agents
- Propolis
Other Study ID Numbers
- 2015-c03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaNot yet recruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Propolis spray
-
Universidade Federal do ParaCompleted
-
Taipei Medical UniversityUnknownOral MucositisTaiwan
-
Federal University of Minas GeraisCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional...CompletedStreptococcal Infections | Saliva Altered
-
Nourhan M.AlyAlexandria UniversityCompletedEarly Childhood CariesEgypt
-
Shanghai Greenvalley Pharmaceutical Co., Ltd.CompletedStable Angina PectorisChina
-
Mashhad University of Medical SciencesCompletedRadiation-induced Mucositis of Oral Mucous MembranesIran, Islamic Republic of
-
Trabzon Kanuni Education and Research HospitalActive, not recruiting
-
Federal University of Minas GeraisConselho Nacional de Desenvolvimento Científico e Tecnológico; Fundação de...CompletedGingivitis | Dental PlaqueBrazil
-
University of Sao Paulo General HospitalHospital Sao Rafael; Alagoas State University of Health Science , Maceió ,...CompletedChronic Kidney Disease Requiring Chronic DialysisBrazil
-
Taipei Medical UniversityNot yet recruitingOral Mucositis | Microbiota | Symptoms and Signs